The business model of Valneva SE revolves around developing, manufacturing, and commercializing vaccines for infectious diseases. As a biotechnology company, Valneva focuses on researching and creating innovative vaccines to prevent diseases such as Japanese encephalitis, Lyme disease, and COVID-19. By leveraging its expertise in vaccine manufacturing and strong partnerships with global organizations, the company aims to address unmet medical needs worldwide. Valneva's business model aligns with its commitment to advancing public health and improving lives through the development and production of safe, effective, and high-quality vaccines.

Valneva SE is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Valneva SE in the market are companies such as Pfizer, Moderna, GlaxoSmithKline, and Sanofi.

Valneva SE is a leading biotechnology company that specializes in the development, manufacturing, and commercialization of vaccines. With a strong focus on infectious diseases, Valneva has a rich history and background in delivering innovative and effective vaccination solutions. Founded in 2013 through the merger of Vivalis and Intercell, Valneva has emerged as a key player in the biopharmaceutical industry. The company has a diverse product portfolio, including vaccines for diseases like Lyme disease, Japanese encephalitis, and cholera. Valneva SE has built a reputation for its commitment to research and development, ensuring the continued advancement of healthcare solutions globally.

Valneva SE, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully completed Phase 3 clinical trials for its Lyme disease vaccine candidate, VLA15, which demonstrated promising efficacy and safety profiles. Valneva also secured a strategic partnership with the US government to support the development and supply of its Zika vaccine, which further highlights the company's expertise in vaccine development. Additionally, Valneva has consistently delivered on its partnerships and collaborations, such as its successful collaboration with Bavarian Nordic to develop innovative vaccines. These achievements showcase Valneva SE's dedication to advancing healthcare through its pioneering vaccine technologies and strategic collaborations.

Valneva SE is primarily present in various countries and regions across the globe. As a multinational biotechnology company, Valneva SE has a significant presence in Europe, including countries like France, Austria, and Sweden. Additionally, the company operates in North America, with a notable presence in the United States and Canada. Valneva SE's global reach extends to regions such as Asia, where it has a strong presence in Japan and China. Furthermore, Valneva SE also has a presence in the Middle East and Africa, with operations in countries like the United Arab Emirates and Egypt.

Analysts currently set an average price target of 7,37 EUR for the Valneva stock (median: 7,85 EUR), implying +242,9 % versus the latest price. The consensus is based on 11 analyst ratings.

Valneva Analyytikkojen kursstavoitteet 2026

11 analysts currently rate the Valneva stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Valneva to generate revenue of 152,15 M EUR and earnings per share of −0,34 EUR.

Valneva Analyytikkojen kursstavoitteet 2026

The Valneva share (VLA.PA) is listed on 11 stock exchanges, including: XETRA (AYJ.DE), Frankfurt (AYJ.F), München (AYJ.MU), Düsseldorf (AYJ.DU), Hamburg (AYJ.HM), London (0OB3.L), London (0OB3.L), Wien (VLA.VI).

Valneva SE is a biopharmaceutical company specializing in the development and marketing of vaccines for infectious diseases. The company was founded in 2013 through the merger of Vivalis and Intercell and is headquartered in Lyon, France. Valneva operates three business units: human vaccines, animal vaccines, and end-to-end services for life science companies. In the human vaccines area, Valneva focuses on the development and marketing of vaccines against diseases such as cholera, Lyme disease, Zika, and COVID-19. The company currently has two products on the market: Ixiaro, a vaccine against Japanese encephalitis, and Dukoral, a vaccine against cholera. In collaboration with Dynavax Technologies, Valneva is currently working on the development of a COVID-19 vaccine. In the animal vaccines area, Valneva has a wide portfolio of vaccines for livestock and pets, including vaccines against diseases such as swine fever, rabies, avian disease, and Lyme disease. Valneva is also a leader in the development of vaccines for tick-borne encephalitis in dogs and humans. In the end-to-end services division, Valneva provides customized solutions for the development, manufacturing, and packaging of biological products and vaccines for other companies. The company has extensive expertise in cell line development, analytics, formulation development, process optimization, GMP production, and quality control. Valneva's business model is based on research and development of vaccines against pathogens and provides special added value to its customers through its extensive experience and expertise in vaccine research and manufacturing. This includes the provision of products that are widely used in today's world. The company actively participates in the development of innovative technologies and research in areas where there is high demand for solutions. Valneva's approach to providing customized solutions to its customers ensures high customer satisfaction. Valneva derives the majority of its revenue from the sales of vaccines against human and animal diseases, making it an important player in the global healthcare industry. The growing demand for vaccines against diseases around the world, particularly in the area of novel Sars-CoV-2 viruses, gives the company a significant boost. In 2019, Valneva's revenue was 126 million euros, maintaining a very good growth trajectory. Valneva employs more than 500 employees at various locations in Europe and North America and enjoys a reputation as an innovation leader in the biopharmaceutical industry.

odotettu liikevaihto Valneva on 152,15 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Valneva on −59,47 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Valneva:n hinta-voitto-suhde (P/E) on tällä hetkellä −6,26. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Valneva-osakkeen arvostusta.

Valneva:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,45. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Valneva-osakkeen arvostuskennuslukuna.

Valneva:n Eulpool-laatuscore on 2/10.

Valneva:n ISIN on FR0004056851. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Valneva:n WKN on A0MVJZ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Valneva:n ticker on VLA.PA. Tämä pörssinoteeraus käytetään Valneva-osakkeiden kauppaan pörssissä.

Valneva maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Valneva kuuluu sektoriin 'Terveydenhuolto'.

Valneva:n osingot jaetaan valuutassa EUR.